Stem cell transplant ideal for patients with higher-risk MDS

06/26/2013 | MedPage Today (free registration) · DailyRx.com

A study in the Journal of Clinical Oncology found that reduced-intensity allogeneic stem cell transplantation is the best fit for many patients ages 60 and older with intermediate-to-high-risk myelodysplastic syndrome. For these patients, early treatment boosted overall life expectancy by an average of eight months compared with patients who received supporting therapies. Survival rates for low-risk MDS were better with nontransplant therapies. "The hope is that this study will at least inform the decision-making process and that older patients with high-risk MDS will at least be referred for [transplant] consultation," said researcher John Koreth of Boston's Dana-Farber Cancer Institute and Harvard Medical School.

View Full Article in:

MedPage Today (free registration) · DailyRx.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL